Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-009754
Filing Date
2025-05-12
Accepted
2025-05-13 09:19:21
Documents
19
Period of Report
2025-05-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14-a.htm   iXBRL DEF 14A 695396
2 GRAPHIC formdef14a_001.jpg GRAPHIC 117943
3 GRAPHIC formdef14a_002.jpg GRAPHIC 119540
4 GRAPHIC proxy_001.jpg GRAPHIC 886361
5 GRAPHIC proxy_002.jpg GRAPHIC 656264
  Complete submission text file 0001641172-25-009754.txt   5401013

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20241231.xsd EX-101.SCH 8075
7 XBRL DEFINITION FILE mtnb-20241231_def.xml EX-101.DEF 14054
8 XBRL LABEL FILE mtnb-20241231_lab.xml EX-101.LAB 75585
9 XBRL PRESENTATION FILE mtnb-20241231_pre.xml EX-101.PRE 48742
21 EXTRACTED XBRL INSTANCE DOCUMENT formdef14-a_htm.xml XML 81764
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38022 | Film No.: 25937512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)